KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Inventory: 2010-2025

Historic Change in Inventory for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $1.1 million.

  • Halozyme Therapeutics' Change in Inventory rose 155.61% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 58.83%. This contributed to the annual value of $67.4 million for FY2024, which is 150.64% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Change in Inventory stood at $1.1 million for Q3 2025, which was down 92.43% from $14.5 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Change in Inventory high stood at $40.2 million for Q1 2024, and its period low was -$6.3 million during Q1 2022.
  • In the last 3 years, Halozyme Therapeutics' Change in Inventory had a median value of $7.2 million in 2023 and averaged $10.0 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Change in Inventory slumped by 172.75% in 2021 and then skyrocketed by 17,717.44% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Change in Inventory (Quarterly) stood at -$2.2 million in 2021, then spiked by 232.72% to $2.9 million in 2022, then crashed by 149.88% to -$1.5 million in 2023, then skyrocketed by 625.94% to $7.7 million in 2024, then surged by 155.61% to $1.1 million in 2025.
  • Its Change in Inventory was $1.1 million in Q3 2025, compared to $14.5 million in Q2 2025 and $586,000 in Q1 2025.